1)Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1(1M tegafur-0.4M gimestat-1M otastat potassium)in advanced gastric cancer patients. Eur J Cancer 34 : 1715-1720, 1998
2)Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58 : 191-197, 2000
3)Sugimachi K, Maehara Y, Horikoshi N, et al. A phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57 : 202-210, 1999
4)栗原稔,小泉和三郎,長谷川浩一,他.胃癌の診断と治療―ティーエスワン.日本臨牀 59(増刊4): 393-397, 2001
5)Sasaki T. Current topics of S-1 at the 74th Japanese gastric cancer congress. Gastric Cancer 6(Suppl 1): 9-12, 2003
6)白坂哲彦, 島本雄司, 加藤利幸, 他. Biochemical Modulationを応用した腫瘍選択毒性の高い新規5-Fluorourasil系抗癌剤S-1の基礎的研究.癌と化学療法 25 : 371-384, 1998
7)Shirasaka T, Shimamoto Y, Ohshimo H, et al. Development of novel form of an oral 5-fluorouracil derivative(S-1)directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 : 548-557, 1996
8)道上慎也,矢田克嗣,森田昌宏,他.TS-1投与が奏効した進行胃癌の1 例.癌と化学療法 31 : 921-923, 2004
9)佐藤温,山本亘,竹渕一宏,他.在宅化学療法と外来化学療法.日本臨牀 59 : 616-620, 2001